Peptide · Performance & growth
CJC-1295 is a GHRH analog often paired with Ipamorelin. Two forms exist: with DAC (longer half-life) and without DAC (Mod GRF 1-29, shorter pulse).
CJC-1295 is a GHRH analog often paired with Ipamorelin. Two forms exist: with DAC (longer half-life) and without DAC (Mod GRF 1-29, shorter pulse).
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. Two forms exist: CJC-1295 with DAC (drug affinity complex) has a half-life of ~8 days due to albumin binding, providing sustained GHRH stimulation; CJC-1295 without DAC (also called Mod GRF 1-29) has a short half-life and produces pulsatile GHRH stimulation. Both stimulate the pituitary to release growth hormone, but through a different receptor than ipamorelin (GHRH receptor vs ghrelin receptor) — which is why the two peptides are commonly combined for additive effects.
Limited human trials.
Compounded — not FDA-approved.
Common protocols:
Dosing in research and clinical-use contexts varies. Specific protocols should always be set by a prescribing clinician, not by patient-direct sources.
Generally well-tolerated. Reported side effects: injection-site irritation, water retention, transient flushing, mild fatigue in the first week. The DAC form is more likely to produce sustained side effects due to the long half-life. Long-term safety is not well-studied.
The standard stack is CJC-1295 + ipamorelin. Patients adding tissue-repair effects layer BPC-157 + TB-500. Patients prioritizing visceral fat reduction may substitute tesamorelin (a more potent GHRH analog with FDA approval for HIV lipodystrophy).
Most peptides discussed on this page are compounded products requiring a prescription from a licensed clinician. Reputable telehealth peptide programs include physician-led oversight, accredited compounding pharmacies, and clear regulatory framing. For weight-management GLP-1 programs, see our provider reviews.
CJC-1295 is a GHRH analog often paired with Ipamorelin. Two forms exist: with DAC (longer half-life) and without DAC (Mod GRF 1-29, shorter pulse).
Compounded — not FDA-approved.
Uses include: GH support, Recovery, Body composition support (research). This is research and clinical-use context, not a recommendation. Always work with a licensed clinician.
Limited human trials.
Reported dosing: 100–300 mcg with Ipamorelin. Actual dosing should always be determined by your prescribing clinician, not by online sources.
DAC offers convenience (twice-weekly dosing). No DAC produces more physiologic pulsatile GH release, which some clinicians prefer. Most newer protocols use the no-DAC form for daily pulse-mimicking stacks with ipamorelin.
Yes, but the combination produces greater GH release than either alone due to the dual-receptor mechanism.